联交所更新生物科技公司指引信
联交所公布,昨日(10日)更新了有关生物科技公司上市文件披露事宜的指引信。更新後的指引信(HKEX-GL107-20)就相关上市申请人呈列公正、不偏不倚和准确的披露资料,以及联交所预期根据《主板规则》第十八A章上市的生物科技公司披露若干主要业务和产品范围资料等事宜提供指引。
港交所上市科主管陈翊庭表示,自2018年4月《上市规则》新增第十八A章以来,来自生物科技公司的上市申请宗数增长可观,公司类型亦更见多元化。随着香港生物科技行业的发展愈益深广,认为有必要提供进一步指引,以提升生物科技公司上市文件的披露。
公布指,本港现时根据第十八A章在港上市的生物科技公司共有30家,合共集资780亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.